Default Mode Network Modulation by Psychedelics: A Systematic Review.

James J Gattuso, Daniel Perkins, Simon Ruffell, Andrew J Lawrence, Daniel Hoyer, Laura H Jacobson, Christopher Timmermann, David Castle, Susan L Rossell, Luke A Downey, Broc A Pagni, Nicole L Galvão-Coelho, David Nutt, Jerome Sarris

Journal: The international journal of neuropsychopharmacology 2023;26(3):155-188

PMID: 36272145

Abstract

Psychedelics are a unique class of drug that commonly produce vivid hallucinations as well as profound psychological and mystical experiences. A grouping of interconnected brain regions characterized by increased temporal coherence at rest have been termed the Default Mode Network (DMN). The DMN has been the focus of numerous studies assessing its role in self-referencing, mind wandering, and autobiographical memories. Altered connectivity in the DMN has been associated with a range of neuropsychiatric conditions such as depression, anxiety, post-traumatic stress disorder, attention deficit hyperactive disorder, schizophrenia, and obsessive-compulsive disorder. To date, several studies have investigated how psychedelics modulate this network, but no comprehensive review, to our knowledge, has critically evaluated how major classical psychedelic agents-lysergic acid diethylamide, psilocybin, and ayahuasca-modulate the DMN. Here we present a systematic review of the knowledge base. Across psychedelics there is consistent acute disruption in resting state connectivity within the DMN and increased functional connectivity between canonical resting-state networks. Various models have been proposed to explain the cognitive mechanisms of psychedelics, and in one model DMN modulation is a central axiom. Although the DMN is consistently implicated in psychedelic studies, it is unclear how central the DMN is to the therapeutic potential of classical psychedelic agents. This article aims to provide the field with a comprehensive overview that can propel future research in such a way as to elucidate the neurocognitive mechanisms of psychedelics.

© The Author(s) 2022. Published by Oxford University Press on behalf of CINP.

Address: MDHS, University of Melbourne, Parkville, Victoria, Australia.; Florey Department of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia.; Psychae Institute, Melbourne, Victoria, Australia.; School of Social and Political Science, University of Melbourne, Australia.; Centre for Mental Health, Swinburne University, Hawthorn, Victoria, Australia.; The Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK.; The Scripps Research Institute, Department of Molecular Medicine, La Jolla, California, USA.; Centre for Psychedelic Research, Division of Psychiatry, Imperial College London, UK.; Department of Psychiatry, University of Toronto, Canada.; Centre for Human Psychopharmacology, Swinburne University, Hawthorn, Victoria, Australia.; College of Health Solutions, Arizona State University, Tempe, Arizona, USA.; Department of Physiology and Behavior, Universidade Federal do Rio Grande do Norte, Brazil.; NICM Health Research Institute, Western Sydney University, Westmead, New South Wales, Australia.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.